Literature DB >> 9721235

Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid.

K A Staschke1, S D Hatch, J C Tang, W J Hornback, J E Munroe, J M Colacino, M A Muesing.   

Abstract

Entry of influenza virus into the host cell is dependent on the fusion of the viral envelope with the endosomal membrane and is mediated by a low-pH-induced change of the viral hemagglutinin (HA) to a conformation that is fusogenic. A compound related to podocarpic acid (180299) was identified that inhibits multicycle replication of influenza A/Kawasaki/86 (H1N1) virus in culture. Treatment of Madin-Darby canine kidney (MDCK) cells with 180299 at 1 h before infection resulted in the inhibition of viral protein synthesis. Addition of 20 microgram of 180299/ml at 1 h p.i. had no effect, indicating that 180299 affects an early step of the influenza viral replication cycle. Genetic analysis of reassortants between sensitive and resistant viruses demonstrated that hemagglutinin (HA) conferred the 180299-resistant (180299(r)) phenotype. Twelve independent isolates of influenza A/Kawasaki/86 were selected for resistance to 180299, and sequence analysis revealed that each of these viruses contained amino acid substitutions in the HA. These mutations are dispersed throughout the HA primary amino acid sequence and cluster in one of two regions: the interface between HA1 and HA2 and in a region near the fusion domain of HA2. When compared with the parent virus, the pH-of-inactivation of the resistant mutants was increased by 0.3 to 0.6 pH unit, suggesting that the mutant HAs undergo the conformational change at an elevated pH. Fusion of human erythrocytes to MDCK cells infected with parent influenza A/Kawasaki/86 was inhibited by 180299 (0.1-10 microgram/ml) in a concentration-dependent manner, whereas fusion of erythrocytes to MDCK cells infected with 180299(r) mutants was not affected. These results suggest that 180299 interacts with the neutral pH conformation of influenza A HA and prevents the low-pH-induced change of HA to its fusogenic conformation. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721235     DOI: 10.1006/viro.1998.9273

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion.

Authors:  C Cianci; K L Yu; D D Dischino; W Harte; M Deshpande; G Luo; R J Colonno; N A Meanwell; M Krystal
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

2.  Phenolic diterpenoid derivatives as anti-influenza a virus agents.

Authors:  Zhao Dang; Katherine Jung; Lei Zhu; Hua Xie; Kuo-Hsiung Lee; Chin-Ho Chen; Li Huang
Journal:  ACS Med Chem Lett       Date:  2015-01-29       Impact factor: 4.345

3.  Design and synthesis of benzenesulfonamide derivatives as potent anti-influenza hemagglutinin inhibitors.

Authors:  Guozhi Tang; Xianfeng Lin; Zongxing Qiu; Wentao Li; Lei Zhu; Lisha Wang; Shaohua Li; Haodong Li; Wenbin Lin; Mei Yang; Tao Guo; Li Chen; Daniel Lee; Jim Z Wu; Wengang Yang
Journal:  ACS Med Chem Lett       Date:  2011-06-07       Impact factor: 4.345

Review 4.  Recent progress in structure-based anti-influenza drug design.

Authors:  Juan Du; Timothy A Cross; Huan-Xiang Zhou
Journal:  Drug Discov Today       Date:  2012-06-13       Impact factor: 7.851

5.  Experience in Nutrition Management of Diabetes-Affected COVID-19 Patients.

Authors:  Behnaz Abiri; Paul C Guest; Mohammadreza Vafa
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Authors:  Arnab Basu; Aleksandar Antanasijevic; Minxiu Wang; Bing Li; Debra M Mills; Jessica A Ames; Peter J Nash; John D Williams; Norton P Peet; Donald T Moir; Mark N Prichard; Kathy A Keith; Dale L Barnard; Michael Caffrey; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

7.  Orally active fusion inhibitor of respiratory syncytial virus.

Authors:  Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley Pearce; Alan Wang; Rita Civiello; Stacey Voss; Guangxiang Luo; Kathy Kadow; Eugene V Genovesi; Brian Venables; Hatice Gulgeze; Ashok Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard Colonno; Junius Clark; Nicholas Meanwell; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening.

Authors:  Marco Weisshaar; Robert Cox; Zachary Morehouse; Shiva Kumar Kyasa; Dan Yan; Phil Oberacker; Shuli Mao; Jennifer E Golden; Anice C Lowen; Michael G Natchus; Richard K Plemper
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

9.  Identification of Novel Fusion Inhibitors of Influenza A Virus by Chemical Genetics.

Authors:  Kin Kui Lai; Nam Nam Cheung; Fang Yang; Jun Dai; Li Liu; Zhiwei Chen; Kong Hung Sze; Honglin Chen; Kwok-Yung Yuen; Richard Yi Tsun Kao
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

Review 10.  Antiviral strategies against influenza virus: towards new therapeutic approaches.

Authors:  Arianna Loregian; Beatrice Mercorelli; Giulio Nannetti; Chiara Compagnin; Giorgio Palù
Journal:  Cell Mol Life Sci       Date:  2014-04-04       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.